GDA-201 is under clinical development by Gamida Cell and currently in Phase II for Follicular Lymphoma. According to GlobalData, Phase II drugs for Follicular Lymphoma have a 46% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how GDA-201’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
GDA-201 is under development for the treatment of refractory/relapsed multiple myeloma, B-cell non-Hodgkin lymphoma including diffuse large B cell lymphoma, mantle cell lymphoma, marginal zone b-cell lymphoma and follicular lymphoma. The therapeutic candidate is administered as an intravenous infusion. The therapeutic candidate comprises of NK cells. It is developed based on NAM platform technology and editas medicine’s CRISPR technology. The therapeutic candidate was also under development for the treatment of leukemias.
Gamida Cell overview
Gamida Cell (Gamida) is a health care company. It offers cell therapy developing cell and immune therapy technologies for treating blood cancers and serious blood disorders. Its pipeline products include Omidubicel an advanced cell therapy being developed as an allogeneic hematopoietic stem cell (bone marrow) transplant solution for treating hematologic malignancies and severe aplastic anemia; GDA-201 an innate natural killer cell immunotherapy used for the treatment of hematologic and solid tumors. Gamida utilizes NAM technology platform to develop its products. Gamida is headquartered in Jerusalem, Israel.
For a complete picture of GDA-201’s drug-specific PTSR and LoA scores, buy the report here.